Karen C M Moraes
Overview
Explore the profile of Karen C M Moraes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Campos-Pereira F, Goncalves L, Jardim R, Cagnoni L, Moraes K, Marin-Morales M
Toxicol In Vitro
. 2025 Mar;
:106048.
PMID: 40086645
Decomposing bodies release necro-leachate, a toxic fluid containing harmful compounds such as biogenic amines. This study investigated the genotoxic effects of the different concentrations (0.5, 1.4, 2.3, 3.2 mM) of...
2.
Porto-Barbosa T, Ramos L, Pansa C, Molica L, Malaspina O, Moraes K
PLoS One
. 2024 Nov;
19(11):e0313185.
PMID: 39514580
Metabolic associated fatty liver disease (MAFLD) is considered an indicator of metabolic syndrome, which affects millions of people around the world and no effective treatment is currently available. MAFLD involves...
3.
Pansa C, Molica L, de Oliveira Junior F, Santello L, Moraes K
J Biochem Mol Toxicol
. 2023 Dec;
38(1):e23595.
PMID: 38050659
Nonalcoholic fatty liver disease (NAFLD) is a global public health problem that affects more than a quarter of the population. The development of this disease is correlated with metabolic dysfunctions...
4.
Pansa C, Molica L, Moraes K
Scand J Gastroenterol
. 2022 Nov;
58(5):521-533.
PMID: 36426638
Background: Non-alcoholic fatty liver disease (NAFLD) results from metabolic dysfunctions that affect more than one-third of the world population. Over the last decades, scientific investigations have clarified many details on...
5.
Moraes K, Montagne J
Front Physiol
. 2021 Oct;
12:728407.
PMID: 34603083
Animal experimentation is limited by unethical procedures, time-consuming protocols, and high cost. Thus, the development of innovative approaches for disease treatment based on alternative models in a fast, safe, and...
6.
da Silveira M, Pansa C, Malaspina O, Moraes K
Mol Biol Rep
. 2021 Apr;
48(4):3463-3474.
PMID: 33907947
Hepatocellular carcinoma is one of the most common types of cancer in the world with high mortality rate and new therapies that control of fatty acid metabolism may limit the...
7.
Bueno D, Pedrolli D, Martins P, Bocchini D, Moraes K, Facincani A, et al.
Microorganisms
. 2021 Feb;
9(2).
PMID: 33562149
subsp. () is the causal agent of Asiatic Citrus Canker (ACC), a disease that affects citrus. ACC has no cure, and growers must rely on special agricultural practices to prevent...
8.
Ramos L, Silva C, Pansa C, Moraes K
Expert Rev Gastroenterol Hepatol
. 2020 Sep;
15(1):25-40.
PMID: 32892668
Introduction: Non-alcoholic fatty liver disease (NAFLD) affects ~25% of world population and cases have increased in recent decades. These anomalies have several etiologies; however, obesity and metabolic dysfunctions are the...
9.
Silva C, Ferrari G, Alberici L, Malaspina O, Moraes K
Mol Cell Biochem
. 2020 Mar;
468(1-2):129-142.
PMID: 32185674
Fibrosis process in the liver is a clinical condition established in response to chronic lesions and may be reversible in many situations. In this process, hepatic stellate cells (HSCs) activate...
10.
Miranda J, Scarinci L, Ramos L, Silva C, Goncalves L, de Morais P, et al.
J Biochem Mol Toxicol
. 2019 Nov;
34(1):e22413.
PMID: 31714634
Hepatic diseases leading to fibrosis affect millions of individuals worldwide and are a major public health challenge. Although, there have been many advances in understanding hepatic fibrogenesis, an effective therapy...